Switch theme
Sign up to access all valuation multiples
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
2015
275
LTM Revenue $339M
LTM EBITDA $123M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Krystal Biotech has a last 12-month revenue of $339M and a last 12-month EBITDA of $123M.
In the most recent fiscal year, Krystal Biotech achieved revenue of $291M and an EBITDA of $110M.
Krystal Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Krystal Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $50.7M | $291M | XXX | XXX | XXX |
| Gross Profit | n/a | $47.6M | XXX | XXX | XXX |
| Gross Margin | NaN% | 16% | XXX | XXX | XXX |
| EBITDA | $17.9M | $110M | XXX | XXX | XXX |
| EBITDA Margin | 35% | 38% | XXX | XXX | XXX |
| Net Profit | -$140M | $10.9M | XXX | XXX | XXX |
| Net Margin | -276% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Krystal Biotech's stock price is $169.
Krystal Biotech has current market cap of $4.9B, and EV of $4.3B.
See Krystal Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $4.9B | XXX | XXX | XXX | XXX | $4.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Krystal Biotech has market cap of $4.9B and EV of $4.3B.
Krystal Biotech's trades at 12.7x LTM EV/Revenue multiple, and 35.0x LTM EBITDA.
Analysts estimate Krystal Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Krystal Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.3B | XXX | XXX | XXX |
| EV/Revenue | 14.8x | XXX | XXX | XXX |
| EV/EBITDA | 39.0x | XXX | XXX | XXX |
| P/E | 54.7x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 36.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKrystal Biotech's NTM/LTM revenue growth is 53%
Krystal Biotech's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Krystal Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Krystal Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Krystal Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 473% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 514% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 91% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 58% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Krystal Biotech acquired XXX companies to date.
Last acquisition by Krystal Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Krystal Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Krystal Biotech founded? | Krystal Biotech was founded in 2015. |
| Where is Krystal Biotech headquartered? | Krystal Biotech is headquartered in United States of America. |
| How many employees does Krystal Biotech have? | As of today, Krystal Biotech has 275 employees. |
| Who is the CEO of Krystal Biotech? | Krystal Biotech's CEO is Mr. Krish S. Krishnan. |
| Is Krystal Biotech publicy listed? | Yes, Krystal Biotech is a public company listed on NAS. |
| What is the stock symbol of Krystal Biotech? | Krystal Biotech trades under KRYS ticker. |
| When did Krystal Biotech go public? | Krystal Biotech went public in 2017. |
| Who are competitors of Krystal Biotech? | Similar companies to Krystal Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Krystal Biotech? | Krystal Biotech's current market cap is $4.9B |
| What is the current revenue of Krystal Biotech? | Krystal Biotech's last 12-month revenue is $339M. |
| What is the current EBITDA of Krystal Biotech? | Krystal Biotech's last 12-month EBITDA is $123M. |
| What is the current EV/Revenue multiple of Krystal Biotech? | Current revenue multiple of Krystal Biotech is 12.7x. |
| What is the current EV/EBITDA multiple of Krystal Biotech? | Current EBITDA multiple of Krystal Biotech is 35.0x. |
| What is the current revenue growth of Krystal Biotech? | Krystal Biotech revenue growth between 2023 and 2024 was 473%. |
| Is Krystal Biotech profitable? | Yes, Krystal Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
